Tumor-Infiltrating Lymphocyte Function Predicts Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Authors:
- Joseph Cherng Huei KongJKJoseph Cherng Huei Kong
- Glen Robert GuerraGGGlen Robert Guerra
- Rosemary Magdalena MillenRMRosemary Magdalena Millen
- Sara RothSRSara Roth
- Huiling XuHXHuiling Xu
- Paul Joseph NeesonPNPaul Joseph Neeson
- Phillip Kevin DarcyPDPhillip Kevin Darcy
- Michael Henry KershawMKMichael Henry Kershaw
- Shienny SampurnoSSShienny Sampurno
- Jordane MalaterreJMJordane Malaterre
- David Shi Hao LiuDLDavid Shi Hao Liu
- Toan Duc PhamTPToan Duc Pham
Open Access
- 1 November 2018
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 2 (2) , 1-15
Abstract
Purpose: The presence of tumor-infiltrating lymphocytes (TILs) in tumors is superior to conventional pathologic staging in predicting patient outcome. However, their presence does not define TIL functionality. Here we developed an assay that tests TIL cytotoxicity in patients with locally advanced rectal cancer before definitive treatment, identifying those who will obtain a pathologic complete response (pCR). We also used the assay to demonstrate the rescue of TIL function after checkpoint inhibition blockade (CIB). Patients and Methods: Thirty-four consecutive patients were identified initially, with successful completion of the assay before surgery in those 17 patients who underwent full treatment. An in vitro cytotoxic assay of rectal cancer tumoroids cocultured with patient-matched TILs was established and validated. Newly diagnosed patients were recruited with pretreatment biopsy specimens processed within 1 month. Evaluation of TIL-mediated tumoroid lysis was performed by measuring the mean fluorescence intensity of cell death marker, propidium iodide. CIB (anti–programmed cell death protein 1 [anti–PD-1] antibody) response was also assessed in a subset of patient specimens. Results: Six of the 17 patients achieved an objective pCR on final evaluation of the resected specimen after neoadjuvant chemoradiotherapy. Cytotoxic killing identified the pCR group with a higher mean fluorescence intensity (27,982 [95% CI, 25,340 to 30,625]) compared with the non-pCR cohort (12,428 [95% CI, 9,434 to 15,423]; p < .001). Assessment of the effectiveness of CIB revealed partial restoration of cytotoxicity in TILs with increased PD-1 expression with anti–PD-1 antibody exposure. Conclusion: Evaluating TIL function can be undertaken within weeks of the diagnostic biopsy, affording the potential to alter patient management decisions and refine selection for a watch-and-wait protocol. This cytotoxic assay also has the potential to serve as a platform to assist in the additional development of CIB.Keywords
This publication has 41 references indexed in Scilit:
- A single‐centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management?Colorectal Disease, 2012
- Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancerBritish Journal of Surgery, 2012
- Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal CancerJournal of Clinical Oncology, 2011
- Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiationCancer, 2011
- Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's EpitheliumGastroenterology, 2011
- Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancerRadiation Oncology, 2011
- Preoperative Chemoradiation With Irinotecan and Capecitabine in Patients With Locally Advanced Resectable Rectal Cancer: Long-Term Results of a Phase II StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Clinical Examination Following Preoperative Chemoradiation for Rectal Cancer Is Not a Reliable Surrogate End PointJournal of Clinical Oncology, 2005
- Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation TherapyAnnals of Surgery, 2004